国际妇产科学杂志 ›› 2026, Vol. 53 ›› Issue (3): 273-277.doi: 10.12280/gjfckx.20251265

• 妇科肿瘤研究:综述 • 上一篇    下一篇

LPCAT1在妇科恶性肿瘤中的研究进展

郑晓琳, 魏芳()   

  1. 030001 太原山西医科大学第二临床医学院(郑晓琳);山西医科大学第二医院妇产科(魏芳)
  • 收稿日期:2025-11-13 出版日期:2026-06-15 发布日期:2026-07-06
  • 通讯作者: 魏芳 E-mail:2yuanweifang@163.com

Research Progress on LPCAT1 in Gynecological Malignancies

ZHENG Xiao-lin, WEI Fang()   

  1. Second Clinical Medical College, Shanxi Medical University, Taiyuan 030001, China (ZHENG Xiao-lin); Department of Obstetrics and Gynecology, Second Hospital of Shanxi Medical University, Taiyuan 030001, China (WEI Fang)
  • Received:2025-11-13 Published:2026-06-15 Online:2026-07-06
  • Contact: WEI Fang E-mail:2yuanweifang@163.com

摘要:

近年来,宫颈癌、子宫内膜癌及卵巢癌等妇科恶性肿瘤的发病率呈上升趋势,并逐渐向年轻人群延伸,严重威胁女性生命健康,虽经规范化治疗可使部分患者受益,但仍存在肿瘤异质性强、复发转移率高及耐药等难题,导致整体预后仍不理想,亟需筛选用于精准治疗及预后评估的新型分子靶点。溶血磷脂酰胆碱酰基转移酶1(lysophosphatidylcholine acyltransferase 1,LPCAT1)是一种能够维持细胞膜稳态和脂质代谢平衡的分子,在宫颈癌、子宫内膜癌和卵巢癌中高表达,可通过磷脂代谢、上皮-间质转化、铁死亡和胆固醇代谢等途径,促进肿瘤细胞的增殖、迁移和侵袭,与肿瘤的高侵袭性、转移性以及较差的预后密切相关。深入研究LPCAT1的分子机制及其临床应用,尤其是针对LPCAT1的抑制策略,有望为妇科恶性肿瘤的早期诊断、预后评估及靶向治疗提供重要支持。

关键词: 溶血磷脂酰胆碱类, 酰基转移酶类, 生殖器肿瘤,女(雌)性, 分子靶向治疗, 脂质代谢

Abstract:

In recent years, the incidence of gynecological malignancies such as cervical cancer, endometrial cancer, and ovarian cancer has been increasing, gradually extending to younger populations and posing a serious threat to women's life and health. Although standardized treatments have benefited some patients, challenges such as strong tumor heterogeneity, high rates of recurrence and metastasis, and drug resistance persist, resulting in suboptimal overall prognosis. There is an urgent need to identify novel molecular targets for precise therapy and prognostic evaluation. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) is a molecule that maintains cellular membrane homeostasis and lipid metabolic balance. It is highly expressed in cervical cancer, endometrial cancer, and ovarian cancer, promoting tumor cell proliferation, migration, and invasion through pathways such as phospholipid metabolism, epithelial-mesenchymal transition, ferroptosis, and cholesterol metabolism. LPCAT1 is closely associated with high tumor invasiveness, metastasis, and poor prognosis. In-depth investigation into the molecular mechanisms and clinical applications of LPCAT1, particularly inhibitory strategies targeting LPCAT1, is expected to provide important support for early diagnosis, prognosis evaluation, and targeted therapy of gynecological malignancies.

Key words: Lysophosphatidylcholines, Acyltransferases, Genital neoplasms, female, Molecular targeted therapy, Lipid metabolism